toripalimab + JS107

Tuoyi + JS107 is an investigational combination therapy consisting of toripalimab (Tuoyi), a humanized recombinant monoclonal antibody targeting programmed cell death protein 1 (PD-1), and JS107, an antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2). Developed by Junshi Biosciences, JS107 is composed of a humanized anti-CLDN18.2 monoclonal antibody conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE) via a protease-cleavable valine-citrulline linker. The combination is designed to exploit the synergistic effects of immune checkpoint inhibition and targeted cytotoxic payload delivery. It is currently in clinical development, including a Phase III trial in combination with XELOX chemotherapy (oxaliplatin and capecitabine) as a first-line treatment for patients with CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.